|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-3-14
|
|
pubmed:abstractText |
To select a daily dose of arzoxifene (LY353381), a selective estrogen receptor modulator, for use in future studies in women with locally advanced or metastatic breast cancer who are either potentially tamoxifen sensitive (TS) or tamoxifen refractory (TR).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/LY 353381,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1007-14
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12637464-Adult,
pubmed-meshheading:12637464-Aged,
pubmed-meshheading:12637464-Aged, 80 and over,
pubmed-meshheading:12637464-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12637464-Breast Neoplasms,
pubmed-meshheading:12637464-Dose-Response Relationship, Drug,
pubmed-meshheading:12637464-Double-Blind Method,
pubmed-meshheading:12637464-Drug Administration Schedule,
pubmed-meshheading:12637464-Drug Resistance, Neoplasm,
pubmed-meshheading:12637464-Endometrium,
pubmed-meshheading:12637464-Estrogen Receptor Modulators,
pubmed-meshheading:12637464-Female,
pubmed-meshheading:12637464-Humans,
pubmed-meshheading:12637464-Middle Aged,
pubmed-meshheading:12637464-Patient Selection,
pubmed-meshheading:12637464-Piperidines,
pubmed-meshheading:12637464-Receptors, Estrogen,
pubmed-meshheading:12637464-Survival Analysis,
pubmed-meshheading:12637464-Tamoxifen,
pubmed-meshheading:12637464-Thiophenes,
pubmed-meshheading:12637464-Treatment Outcome,
pubmed-meshheading:12637464-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
|
|
pubmed:affiliation |
M.D. Anderson Cancer Center and US Oncology Research, Houston, and Baylor-Sammons Cancer Center and Texas Oncology, Dallas, TX. 77030, USA. abuzdar@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
